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INTRODUCTION:  Primary  renal  Ewing  sarcoma/PNET  is an  uncommon  and  very  aggressive  tumor.
PRESENTATION OF  CASE:  We  report  the  case  of a young  woman  who  underwent  nephrectomy  for  a renal
mass  from  unknown  etiology.  Histologic  analysis  found  small  tumoral  cells  in rosette  formation,  and
immunohistochemical  staining  was  positive  for  CD99,  and  focally  positive  for  vimentin  and  Protein  S-
100.  A  post  operative  abdominal  computed  tomography  (CT)  scan  revealed  a  residual  renal  processus
with  hepatic  wounds  and  abdominal  metastatic  nodes.
After 6 cycles  of  chemotherapy  including  Vincristine,  Doxorubicin,  Cyclophosphamide,  the  response
was  considered  as good.omplete response DISCUSSION: Ewing’s  sarcoma/PNET  of  kidney  is a member  of  the  family  of  small  round  cell  tumors  and
it  should  be differentiated  from  Wilms  tumor,  neuroblastoma,  rhabdomyosarcoma  and  lymphoblastic
lymphoma.  The  principle  management  of  its treatment  have  been  extrapolated  from  the  treatment  of
osseous  Ewing  sarcoma  of bone.
CONCLUSION: Despite  aggressive  treatment,  primary  renal  Ewing  sarcoma/PNET  has  a poor  prognosis.  It
requires  a  multidisciplinary  approach  including  oncologists,  urologists  and  radiation  oncologists.
ical A© 2012 Surg
. Introduction
The extra-osseous Ewing’s sarcoma represents nearly 6% of the
wing’s sarcoma family of tumors (ESFT). It was introduced initially
n 1969 by Tefft who reported a series of ﬁve patients with round
ell tumors that comes from the paravertebral soft tissues.1 It often
nvolves the trunk, the extremities, the soft tissues of head and
eck, and the retroperitoneum.2,3 However, renal localization is
ery rare and has a poor prognosis. Because of the rarity of this
isease, there is no consensus concerning the treatment of renal
wing’s sarcoma/PNET.4
We  report the case of a young female patient with a renal
etastatic Ewing’s sarcoma/PNET which was successfully managed
y chemotherapy.
.  Case report
A  40 years old woman was referred to the National Insti-
ute of Oncology with severe back pain one month after a right
ephrectomy, performed because of a renal mass, in a periph-
ral hospital. Only abdominal tenderness was found on clinical
xam. There was no organomegaly and no hematuria. Histological
eport described macroscopically a renal mass about a renal mass
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measuring 190 mm  ×100 mm ×90 mm,  white gray, friable, with
areas of necrosis and hemorrhage. Microscopic examination
showed a malignant tumor composed of monomorphic cells, with
slightly irregular nuclei and dense chromatin. These cells ﬁtted
together in some places forming rosettes (Fig. 1). At immunochem-
istry, the cells were positive for the PNET markers: CD99 and focally
positive for Vimentin anticorps and protein S-100, but negative for
Epithelial membrane antigen (EMA), Leucocyte common antigen
(LCA) and Desmine (Fig. 2).
A post-operative abdominal computed tomography (CT) scan
revealed a residual mass in the right renal space which involved
liver. The mass abutted onto of the duodenum, the right psoas mus-
cle and the right colic ﬂexure. Peritoneal nodes and ascites were also
found. The computed tomography of the thorax, the bone scintigra-
phy, the blood electrolytes and the renal function were all normal.
The disease was staged at IV.
Our patient was treated by six cycles of chemotherapy
every  three weeks including Vincristin 1.4 mg/m2, Adriamycine
60 mg/m2, and Cyclophosphamide 1250 mg/m2. The tolerance of
chemotherapy was good. The response was estimated at 90%
according to the Recist guideline version 1.1. The patient was in
good control for four months after the last cycle of chemotherapy.
3.  Discussion
Open access under CC BY-NC-ND license.Primary renal Primitive NeuroEctodermal Tumor (PNET) is a
very rare condition. The ﬁrst case was  reported by Seemayer et al.5
Since then, there have been about only 60 cases reported in the
BY-NC-ND license.
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Fig. 1. Renal EWS/PNET composed of small round cells with Homer–Wright rosettes
n tumor (HE.G X40).
iterature. Until now, the largest series of rPNET was  published by
uvaraja B and al. This series included 16 patients who were treated
n Tata Memorial Hospital in India.6
The origin of this tumor is unknown, but it seems that it derives
rom cells that migrated from the neural tube, with variable capa-
ility of ectodermal or neuronal differentiation.
The median age of young adult is estimated at 28 years old (range
–69) with a slight male predominance.7 There are no clinical spe-
iﬁc symptoms, and the diagnosis of PNET/Ewing sarcoma of Kidney
s based on histopathology.
Histologically, Ewing sarcoma/PNET is composed by monomor-
hic small cell rounds which form Homer right rosettes.8
mmunohistochemically, the tumor cells are strongly positive for
D99 and Leukemia Virus Integration (FLI)-1.
Using a large panel of immunochemistry markers is often
ssential (Cytokeratine, epithelial membrane antigen, a WT1,
ynaptophysin, muscle speciﬁc actine, Desmine, myogenine, LCA
nd CD45) to exclude other round cells tumors, because of their
mportant similarities.
Thus,  histologists have to recognize other round cells tumors
uch as: rhabdomyosarcoma, Wilms’ tumor, neuroblastoma, clear
ell sarcoma of the kidney, lymphoma, small cell variant of
steosarcoma, desmoplastic small RCT, small cell anaplastic neu-
oendocrine carcinoma, and nephroblastoma.9
The cytogenetics have an important role to play to conﬁrm
he diagnosis, by searching the translocation t (11; 22) (q24; q12)
esulting in the production of the EWS/Friend leukemia virus inte-
ration 1 (FLI-1) fusion.10,11
ig. 2. The tumor cells showed diffuse and strong membranous staining for CD99.PEN  ACCESS
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There is no consensus of treatment for metastatic renal PNET
because of it rarity. The treatment is extrapolated from the treat-
ment of osseous Ewing sarcoma. It is based on combination of
chemotherapy included active drugs such as Doxorubicin (A), Vin-
cristin (V), Cyclophosphamide (C), Ifosfamide (I) and Etoposide (E).
The IESS-III study published in 2003 by Grier conducted in the
pediatric oncology group children’s cancer group (POG-CCG) study
(INT-0091), concluded that patients with non metastatic Ewing sar-
coma were randomized to receive chemotherapy with either VACD
alone or alternating with ifosfamide and etoposide (VACD-IE) for a
total of 17 cycles. The ﬁve event free survival rate was 69% in the
VACD-IE group as compared with 54% in the VACD alone group.
Overall survival was  also signiﬁcantly better among patients in the
VACD-IE group (72% vs 61% in the VACD group). However, the addi-
tion alternating cycles of Ifosfamide (I) and etoposide (E) to the
VDC (vincristin, D-actinomycin, cyclophosphamide) regimen did
not improve the outcome of the patients with metastases.12
Otherwise, the EURO-EWING study is designed to evaluate the
efﬁcacy and safety of multiagent induction chemotherapy with
six courses of vincristine, ifosfamide, doxorubicine, and etopo-
side (VIDE), local treatment (surgery and/or radiotherapy), and
high dose therapy followed by stem cell transplantation in 281
patients with Ewing’s sarcoma with primary disseminated disease.
The event free survival and overall survival rates at 3 years for
the entire study cohort were 27% and 34% respectively. The event
free survival rates were 57% and 25% respectively for patients with
complete and partial response after HDT/SCT. The relevant risk fac-
tors are the patient’s age, tumor volume, and extent of metastatic
spread.13
About 30–40% of patients with Ewing’s sarcoma experience
recurrence. The only prognostic factor identiﬁed in relapse seems
to be time to relapse: patients relapsing later than 2 years from
initial diagnosis have a better outcome. The treatment option for
patient with relapsed or refractory disease participation in clinical
trial. The guidelines proposed the following regimens: Ifosfamide
with etoposide14 and carboplatine, Ifosfamide and etoposide15,
docetaxel in combination with gemcitabine16, Temozolomide and
irinotecan17.
Despite aggressive treatment, the prognosis of rPNET is poor.
The median survival for advanced disease is only 2 years18. In the
retrospective study reported by Yuvaraja (16 patients with renal
PNET/Ewing sarcoma): 5 patients (31%) had metastases (2 lungs,
1 lung and lymph nodes, 1 lymph nodes, and 1 liver). The median
survival was estimated at 15 months.6
In the case we  report, the age of occurrence of rPNET at 40 years
old which is unusual. The diagnosis of PNET/Ewing’s sarcoma of the
kidney was  established on morphologic and immunohistochemical
criteria. We  could not perform molecular analysis, because of a lack
of technical structures.
We  tread our patient with 6 cycles of chemotherapy every three
weeks including: Vincristin 1.4 mg/m2, Adriamycine 60 mg/m2 and
Cyclophosphamide 1250 mg/m2. The response was considered as
good, and the control was  kept for four months. The patient died 4
months later in the unknown circumstances.
4. Conclusion
Because of its rarity, the management of PNET/Ewing sarcoma
of the kidney remains difﬁcult, and the results are uncertain. The
prognosis is poor, despite aggressive treatment. More experiences
are needed to clarify the management strategy.Conﬂict of interest statement
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